The “Final” 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent

This publication has 28 references indexed in Scilit:

• Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents
  Circulation, 2011
• Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions
  JACC: Cardiovascular Interventions, 2010
• A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions
  JACC, 2010
• Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions
  JACC: Cardiovascular Interventions, 2009
• Safety and Efficacy of Drug-Eluting and Bare Metal Stents
  Circulation, 2009
• Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice
  JACC, 2008
• Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
  New England Journal of Medicine, 2007
• Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
  The Lancet, 2004
• A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
  New England Journal of Medicine, 2004
• Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery
  New England Journal of Medicine, 2003